Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $298.09

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received an average recommendation of “Moderate Buy” from the twenty-five brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $298.61.

A number of equities research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Piper Sandler restated an “overweight” rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Finally, Sanford C. Bernstein reduced their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday.

Alnylam Pharmaceuticals Stock Up 1.9 %

ALNY opened at $240.55 on Friday. The company has a fifty day moving average of $249.60 and a two-hundred day moving average of $259.41. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock has a market capitalization of $31.03 billion, a price-to-earnings ratio of -91.81 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same period last year, the firm earned $1.15 earnings per share. The company’s revenue for the quarter was down 33.3% compared to the same quarter last year. On average, research analysts expect that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the completion of the sale, the chief marketing officer now directly owns 15,705 shares of the company’s stock, valued at $3,941,955. The trade was a 10.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,122 shares of company stock valued at $2,540,455 over the last 90 days. 1.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock valued at $589,209,000 after purchasing an additional 66,928 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Alnylam Pharmaceuticals by 3.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock valued at $134,035,000 after buying an additional 16,756 shares during the period. Avoro Capital Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 33.3% in the second quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after acquiring an additional 100,000 shares in the last quarter. Swiss National Bank increased its position in shares of Alnylam Pharmaceuticals by 0.3% during the third quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after acquiring an additional 1,000 shares during the period. Finally, Eagle Asset Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 25.7% in the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock valued at $85,889,000 after acquiring an additional 63,385 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.